Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anne Dyhl-Polk"'
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100892- (2021)
Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, p
Externí odkaz:
https://doaj.org/article/142b694bfd4047ac8e36cd06ff375cce
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Breast cancer is the global leading cause of cancer-related death in women and it represents a major health burden worldwide. One of the promising breast cancer therapeutic avenues is through small molecule inhibitors (SMIs) which have undergone rapi
Externí odkaz:
https://doaj.org/article/80cba12890ed4689a23828add3650b83
Autor:
Marta Kramer Mikkelsen, Nana Aviaja Frederikke Lindblom, Anne Dyhl-Polk, Carsten Bogh Juhl, Julia Sidenius Johansen, Dorte Nielsen
Publikováno v:
Critical reviews in clinical laboratory sciences. 59(7)
Inflammation is an enabling characteristic of the hallmarks of cancer. There has therefore been increasing interest in the clinical value of circulating inflammatory biomarkers in cancer. In this review, we summarize results on C-reactive protein (CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a3428fd0cc31029f3cebbfcace2554
https://pubmed.ncbi.nlm.nih.gov/35403550
https://pubmed.ncbi.nlm.nih.gov/35403550
Autor:
Maya Mazuwin Yahya, Anne Dyhl-Polk, Kah Keng Wong, Siti Muhamad Nur Husna, Faezahtul Arbaeyah Hussain
Publikováno v:
Malaysian Journal of Public Health Medicine. 20:285-306
Breast cancer is the leading cause of cancer-related death in female worldwide. Human epidermal growth factor receptor 2 (HER2) amplification is observed in approximately 20% of breast cancer cases and is associated with poor clinical outcomes. Dual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afb07efc3d22dc58400c199f6267b1e1
https://doi.org/10.37268/mjphm/vol.20/no.2/art.510
https://doi.org/10.37268/mjphm/vol.20/no.2/art.510
Publikováno v:
Cancer Treatment Reviews. 78:17-30
Introduction Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in several types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fdd0475e412c61f84c6eb3b506706b8
https://doi.org/10.1016/j.ctrv.2019.06.005
https://doi.org/10.1016/j.ctrv.2019.06.005
Publikováno v:
Journal of Clinical Medicine
Dyhl-Polk, A, Mikkelsen, M K, Ladekarl, M & Nielsen, D L 2021, ' Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma ', Journal of Clinical Medicine, vol. 10, no. 12, 2662 . https://doi.org/10.3390/jcm10122662
Journal of Clinical Medicine, Vol 10, Iss 2662, p 2662 (2021)
Dyhl-Polk, A, Mikkelsen, M K, Ladekarl, M & Nielsen, D L 2021, ' Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma ', Journal of Clinical Medicine, vol. 10, no. 12, 2662 . https://doi.org/10.3390/jcm10122662
Journal of Clinical Medicine, Vol 10, Iss 2662, p 2662 (2021)
Introduction: Several immune checkpoint inhibitors (CPIs) are under clinical development in hepatocellular carcinoma (HCC) and the field is advancing rapidly. In this comprehensive review, we discuss published results and report on ongoing clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf19e3a7cd094a07b0180077d88c1a3
https://pubmed.ncbi.nlm.nih.gov/34208788
https://pubmed.ncbi.nlm.nih.gov/34208788
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100892-(2021)
Translational Oncology
Lund, C M, Dyhl-Polk, A, Nielsen, D L & Riis, L B 2021, ' Wnt5a expression and prognosis in stage II–III colon cancer ', Translational Oncology, vol. 14, no. 1, 100892 . https://doi.org/10.1016/j.tranon.2020.100892
Translational Oncology
Lund, C M, Dyhl-Polk, A, Nielsen, D L & Riis, L B 2021, ' Wnt5a expression and prognosis in stage II–III colon cancer ', Translational Oncology, vol. 14, no. 1, 100892 . https://doi.org/10.1016/j.tranon.2020.100892
Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83e1ccd42a595caa81374ef8589879d
http://www.sciencedirect.com/science/article/pii/S1936523320303843
http://www.sciencedirect.com/science/article/pii/S1936523320303843
Autor:
Morten Schou, Anne Dyhl-Polk, Stig E. Bojesen, Eva Serup-Hansen, Kirsten Vistisen, Merete Vaage-Nilsen, Anne-Sophie Sillesen, Jens Faber, Dorte Nielsen, Tobias Wirenfeldt Klausen
Publikováno v:
Dyhl-Polk, A, Schou, M, Vistisen, K K, Sillesen, A S, Serup-Hansen, E, Faber, J, Klausen, T W, Bojesen, S E, Vaage-Nilsen, M & Nielsen, D L 2021, ' Myocardial Ischemia Induced by 5-Fluorouracil : A Prospective Electrocardiographic and Cardiac Biomarker Study ', Oncologist, vol. 26, no. 3, pp. e403-e413 . https://doi.org/10.1002/onco.13536
Oncologist
Oncologist
Background Cardiotoxicity induced by 5-fluorouracil (5-FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses of the biomarkers troponin and copeptin in patients receiving 5-FU to increase our underst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992e00cae4c0c182d0c014926bdf2545
https://curis.ku.dk/ws/files/314848932/oncolo_26_3_e403.pdf
https://curis.ku.dk/ws/files/314848932/oncolo_26_3_e403.pdf
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Breast cancer is the global leading cause of cancer-related death in women and it represents a major health burden worldwide. One of the promising breast cancer therapeutic avenues is through small molecule inhibitors (SMIs) which have undergone rapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a666d127d236ccfea0a0c7cc5d0168b1
https://pubmed.ncbi.nlm.nih.gov/30542378
https://pubmed.ncbi.nlm.nih.gov/30542378